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Thioredoxin Modulates Protein
Arginine Deiminase 4
(PAD4)-Catalyzed Citrullination
Mitesh Nagar 1,2, Ronak Tilvawala 1,2 and Paul R. Thompson 1,2*
1Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA,
United States, 2 Program in Chemical Biology, University of Massachusetts Medical School, Worcester, MA, United States
Protein citrullination is a post-translational modification catalyzed by the protein arginine
deiminases (PADs). This modification plays a crucial role in the pathophysiology of
numerous autoimmune disorders including RA. Recently, there has been a growing
interest in investigating physiological regulators of PAD activity to understand the primary
cause of the associated disorders. Apart from calcium, it is well-documented that a
reducing environment activates the PADs. Although the concentration of thioredoxin
(hTRX), an oxidoreductase that maintains the cellular reducing environment, is elevated
in RA patients, its contribution toward RA progression or PAD activity has not been
explored. Herein, we demonstrate that hTRX activates PAD4. Kinetic characterization
of PAD4 using hTRX as the reducing agent yielded parameters that are comparable
to those obtained with a routinely used non-physiological reducing agent, e.g., DTT,
suggesting the importance of hTRX in PAD regulation under physiological conditions.
Furthermore, we show that various hTRXmutants, including redox inactive hTRX variants,
are capable of activating PAD4. This indicates a mechanism that does not require
oxidoreductase activity. Indeed, we observed non-covalent interactions between PAD4
and hTRX variants, and propose that these redox-independent interactions are sufficient
for hTRX-mediated PAD4 activation.
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INTRODUCTION
Protein citrullination is a post-translational modification that converts a positively charged
arginine residue into a neutral citrulline (1, 2). Modifications of such charged residues can alter
various protein properties, including protein-protein interactions and protein-DNA interactions,
with consequent effects on various physiological processes (2–4). For example, histone hyper-
citrullination leads to chromatin decondensation and ultimately the release of neutrophil
extracellular traps (NETs), which are involved in the innate immune response against various
pathogens as well as in the pathogenesis of autoimmune and inflammatory disorders (5–7). In fact,
protein citrullination has been extensively studied in the context of rheumatoid arthritis (RA) due
to the presence of autoantibodies against citrullinated proteins (ACPA) in over 70% of RA patients
(3, 8–10). ACPA are highly specific and widely used for the diagnosis of RA (11, 12). Apart from
autoimmune diseases, like RA, lupus, multiple sclerosis, and ulcerative colitis (13–15), aberrant
citrullination has also been shown to play a role in the pathology of various neurodegenerative
diseases, diabetes, and cancer (16–19). Therefore, the group of enzymes that catalyze protein
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citrullination, the protein arginine deiminases (PADs), are
attractive therapeutic targets (13, 14, 20–24). For this reason,
most PAD-focused studies investigate their pathophysiological
functions rather than their physiological roles under normal
circumstances. Importantly, it is still unclear how PAD activity
is regulated and how aberrant regulation leads to various
pathological conditions.
There are five human PAD isozymes (PAD1-4 and PAD6).
These isozymes are localized in specific tissues to carry out
distinct physiological functions. For example, PAD1 and PAD3
are expressed in the skin and hair follicles and regulate the
cellular architecture. PAD2 and PAD4 play roles in apoptosis,
gene regulation, and NET-formation (2, 6, 25–27). Amongst
the PAD family, PAD2 and PAD4 are of particular interest
because these isozymes are expressed mainly in immune cells
and have been implicated in a variety of autoimmune and
inflammatory disorders (3, 13–15, 28, 29). All the active PADs
(PAD1-4) share similar catalytic mechanisms and their activity is
regulated by calcium through important conformational changes
that facilitate PAD-catalysis (30–32). In addition to calcium,
bicarbonate and GSH regulate PAD2 and PAD4 activity under
physiological conditions (33, 34). Since redox balance is a
necessary requirement for PAD activity, thioredoxin (hTRX), a
12 kDa protein that regulates redox homoeostasis in all tissues
of the human body (35–37), is another candidate that could
impact PAD-catalyzed citrullination. In fact, numerous studies
have shown elevated levels of hTRX in serum and synovial
samples from RA patients (38–42) suggesting hTRX activity
might contribute to RA progression; however its role in PAD
activation has yet been established.
Herein, we report the impact of hTRX on PAD activity using
the synthetic substrate mimic Nα-benzoyl-L-arginine ethyl ester
(BAEE) and verified our results with the physiological substrate
histone H3. Moreover, we used a variety of hTRX mutants to
show that hTRX activates PAD4 in a redox-independent manner.
MATERIALS AND METHODS
Plasmids
His-tagged human wild-type hTRX and C35S, C32/35S, C62S,
C69S, and C73S-hTRX variants were kind gifts from Dr.
Weerapana (Boston College, MA). The C32/35/69S and C62/69S-
hTRX mutants were created in house.
Preparation of Proteins
Thioredoxins
Wild-type hTRX and its mutants were purified in the absence
of any reducing agents as described previously (43). All variants
were fully reduced with DTT (10mM) for 10min at 37◦C (44)
and the excess DTT was removed by exhaustive buffer exchange
using amicon centrifugal filters (3 kDa).
Abbreviations: hTRX, human thioredoxin; GSNO, S-nitrosoglutathione; RA,
rheumatoid arthritis; PAD, protein arginine deiminase; ACPA, anti-citrullinated
protein antibodies; NET, neutrophil extracellular trap; BAEE,Nα-benzoyl arginine
ethyl ester; PBS, phosphate buffered saline; BSA, bovine serum albumin.
PAD4
Purification of human PAD4 was carried out as described
previously (45) but without reducing agent. S-nitrosoglutathione
(GSNO) and H2O2-modified PAD4 were prepared by incubating
PAD4 with GSNO (200µM) or H2O2 (100µM) for 10min
at 37◦C. Excess reagents were removed by exhaustive buffer
exchange using amicon centrifugal filters (10 kDa).
PAD4 Activity Assay
Using BAEE as Substrate
PAD4 activation was determined using a previously described
discontinuous colorimetric assay (45). Briefly, reaction buffer
(Tris-HCl, 100mM; pH 7.6; NaCl, 50mM) containing CaCl2
(10mM), BAEE (10mM), and hTRX (0–10µM) was pre-
incubated at 37◦C for 10min followed by the addition of PAD4
(final concentration of 0.2µM) to initiate the reaction (60 µL
final volume). After 10min, reactions were quenched by adding
200 µL of freshly prepared COLDER solution [H3PO4, 2.25M;
H2SO4, 4.5M; NH4Fe(SO4), 1.5mM; diacetyl monoxime,
20mM; and thiosemicarbazide, 1.5mM] and incubated for
30min at 95◦C for color development. Sample absorbance was
measured at 540 nm to determine the amount citrulline produced
during the course of the reaction using a citrulline standard.
Control activity of PAD4 was measured using a saturating
concentration of DTT (2mM) (45).
Using Histone H3 as Substrate
Previously purified Histone H3 (10µM) (46) was treated with
PAD4 (0.2µM) in reaction buffer containing thioredoxin (0. 0.08,
0.17, 0.33, 0.67, 1.33, and 2.67µM) at 37◦C (total volume 30 µL)
for 10min and then the reaction was quenched using 6X SDS-
PAGE loading dye followed by 10min incubation at 95◦C before
running samples on SDS-PAGE. Separated proteins were then
transferred to PVDF membrane (Bio-Rad) at 80V for 50min.
The membrane was then blocked with PBS containing Tween-20
(0.1%, PBST) and BSA (5%) for 1 h at room temperature before
adding primary antibodies for PAD4 (rabbit, 1:1,000, Proteintech
cat# 7373-1-AP), histone H3 (mouse, 1:1,000, Abcam cat#
ab10799), and histone H3-Cit-2,8,17 (rabbit, 1:1,000, Abcam cat#
ab5103) and further incubated overnight at 4◦C. The next day,
after washing with PBST (3×), the membrane was incubated with
secondary anti-rabbit IgG Licor conjugate antibody (1:5,000) for
1 h at room temperature. Finally, the membrane was imaged and
quantified using LICOR Odyssey Imaging System.
hTRX Activity Assay
The hTRX-activity assay was performed as per themanufacturer’s
instructions (Cayman Chemical Co., cat# 20039). Briefly, various
hTRX variant samples (10 µL of 1.0µM solution) were added
to a 96-well half area black plate followed by addition of
assay buffer (55 µL), human thioredoxin reductase (10 µL of
1.0µM solution), and NADPH (5 µL, diluted according to kit
instructions) to each sample well. The plate was then incubated at
37◦C for 30min. After incubation, fluorescent substrate (20 µL,
diluted according to kit instructions) was added to each sample
as quickly as possible. The plate was immediately placed in an
Envision plate reader (Molecular Devices) and fluorescence was
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FIGURE 1 | Effect of hTRX on PAD4 activity. Rate of citrullination of BAEE by PAD4 in presence of various concentrations of untreated (A) and DTT-treated hTRX
(B). Histone H3 citrullination by PAD4 in the presence of various hTRX concentrations (C). The quantification of the western blot, i.e., citH3/H3 ratio, with increasing
concentration of hTRX (D).
monitored at 480 nm excitation and 520 nm emission for 15min.
Reaction rates were plotted and compared.
hTRX Interaction With PAD4
Size-Exclusion Chromatography
PAD4 (12µM) and hTRX (or its variants, 80µM)were incubated
in size-exclusion buffer (SEC-buffer, Tris-Cl, 100mM; pH 7.6;
NaCl, 50mM, and CaCl2, 10mM) at 37◦C for 10min (final
volume 100 µL). This mixture was diluted with 300 µL of SEC-
buffer and loaded onto a size exclusion column (Superdex 200
10/300 GL, GE Healthcare) attached to an ÄKTA-FPLC. The
proteins were separated with a flow rate of 0.5 mL/min. Peak
fractions (1mL) corresponding to the PAD4 dimer and PAD4
monomer were concentrated 10X and subjected to denaturing
SDS-PAGE followed by blotting on PVDFmembrane (see above).
Primary antibodies against PAD4 (rabbit, 1:1,000, Proteintech
cat# 7373-1-AP) and thioredoxin (mouse, 1:1,000, Abcam cat#
ab16965) were used to evaluate the presence of hTRX in
PAD4 peaks.
Immunoprecipitation (IP)
HL60 cells were grown in RPMI 1640 medium (w/L-
glutamine and HEPES) supplemented with 10% FBS and
penicillin/streptomycin at a density of 3 × 105 cells/mL.
Differentiation of HL60 cells to granulocytes was induced by
1.3% dimethyl sulfoxide (DMSO) and then the cells were allowed
to grow for 4 days before harvesting. After washing the cell
pellet with PBS (3×), cells were lysed using lysis buffer (Tris-Cl,
25mM, pH 7.4; NaCl, 50mM; CaCl2, 2mM and 1% NP40)
containing protease inhibitor cocktail. Clarified cell lysates
(1.2mg total protein) were incubated with anti-PAD4 (4 µg,
rabbit, Proteintech cat# 7373-1-AP) or generic rabbit IgG (4
µg) for overnight at 4◦C with gentle rotation. Protein A/G
plus-agarose beads (100 µL slurry, Santa Cruz Biotechnology)
were added to the mixture and incubated for another 4 h at
4◦C to capture antibody-bound protein complexes. The beads
were then washed (3×) with wash buffer [Tris-Cl, 25mM (pH
7.4); NaCl, 50mM, CaCl2, 2mM; and 0.2% NP-40], and the
protein complexes were eluted using 2 × SDS sample buffer.
Eluted proteins were immunoblotted as mentioned above using
primary antibodies against PAD4 (mouse 1:1,000, Abcam cat#
128086) and thioredoxin (mouse, 1:1,000, Abcam cat# ab16965).
HRP-conjugated goat anti-mouse antibody (1:10,000, Invitrogen
cat # 31432) was used to evaluate the presence of hTRX and
PAD4 in the elution fraction by detecting chemiluminescence
using an ECL kit (GE Healthcare Amersham).
RESULTS
Effect of hTRX on PAD4 Activity
To investigate whether hTRX can influence PAD4 activity,
we used BAEE (Figures 1A,B) and histone H3 as substrates
(Figures 1C,D). Purified hTRX activated PAD4 in a
concentration-dependent manner and displayed saturation
kinetics (Figures 1A,B). Although DTT-treated hTRX showed
better activation (Figure 1B), maximal PAD4 activity was
still observed at 5µM of hTRX (Figures 1A,B). Therefore,
all other kinetic assays were performed using this saturating
concentration of reduced-hTRX.
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FIGURE 2 | Activation of PAD4 in the presence of various reducing agents. (A) Reactivation of GSNO- and H2O2-treated PAD4 by reducing agents. Rate of
citrullination of BAEE by PAD4 [treated with GSNO (200µM) or H2O2 (100µM) for 10min at 37
◦C] measured in presence of hTRX or DTT. (B) Combined effect of
physiological reducing agents on PAD4 activation. PAD4 activity was measured in the presence of various concentrations of GSH containing sub-saturating (0.66µM)
and saturating concentrations of hTRX (5µM).
FIGURE 3 | Kinetic characterization of PAD4. (A) Michaelis-Menten plots of PAD4 with various BAEE concentrations in presence of hTRX (5µM), DTT (2mM), and
buffer as control. Refer to Figure S1 for PAD1, PAD2, and PAD3 data. (B) Calcium-dependence of PAD4 with hTRX and DTT as reducing agents. (C) Kinetic
parameters deduced from (A,B).
Activation of PAD4 With Various Reducing
Agents
The role of the oxidoreductase activity of hTRX was further
evaluated by re-activating PAD4 after mild treatment with thiol-
oxidizing (H2O2) and -nitrosylating (GSNO) agents (Figure 2A).
Under both situations, hTRX revived PAD4 activity; but unlike
control, only 50% (GSNO-treated PAD4) and 75% (H2O2-treated
PAD4) of the activity revived by the in vitro reducing agent
DTT (Figure 2A). Since GSH is a known co-activator of PADs,
the combined effect of hTRX and GSH on PAD4 activity was
also examined. PAD4 activity was measured in the presence of
various concentrations of GSH containing sub-saturating (near
Kd value) and saturating concentrations of hTRX (as determined
in the previous section). As expected both hTRX (5µM) and
GSH (2mM) individually showed activation of PAD4, but when
used in combination there was only slight increase in maximum
activity (Figure 2B).
Kinetic Characterization of PAD4 Using
hTRX as Reducing Agent
Next, the kinetic parameters of PAD4 for BAEE were determined
in the presence of hTRX (khTRXcat = 5.0 ± 0.4 s
−1; KhTRXm =
0.7 ± 0.2mM; KCa2+0.5 = 0.43 ± 0.02mM) and compared to the
kinetic parameters obtained in presence of DTT (kDTTcat = 5.62 ±
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FIGURE 4 | Activation of PAD4 in presence of hTRX variants. (A) Effect of
hTRX mutations and IAA-treatment on its oxidoreductase activity. The hTRX
activity was measured using a kit from Cayman Chemical Co. (cat# 20039).
(B) Effect of various hTRX mutants on the catalytic efficiency of PAD4. Refer to
Table 1 for the raw data. Fold change in thioredoxin activity or thioredoxin
activation efficiency for PAD4 for the hTRX mutants are calculated with respect
to wild-type hTRX.
0.04 s−1; KDTTm = 1.48 ± 0.01mM; K
Ca2+
0.5 = 0.41 ± 0.03mM)
(Figures 3A–C). In both cases, all kinetic parameters including
the Ca2+-dependence, were quite comparable (i.e., within one- to
two-fold), suggesting hTRX could be the major PAD4 reducing
agent under physiological conditions. In addition to PAD4, we
also observed higher PAD1, PAD2, and PAD3 activity with buffer
containing hTRX compared to buffer without any reducing agent,
suggesting that the reducing activity of hTRX can activate all PAD
isozymes (Figure S1).
Impact of Redox-Activity of hTRX on PAD4
Activation
To determine how hTRX activates PAD4, we first created various
thioredoxin mutants and confirmed their oxidoreductase activity
using a commercial assay kit. As expected, none of the hTRX
TABLE 1 | Activation of PAD4 by various hTRX variants.
hTRX Vmax (µM/s) Kd (app) (µM) (Vmax/ET)/Kd (app)
(M−1s−1) × 106
WT 0.83 ± 0.01 0.72 ± 0.05 5.7 ± 0.4
C35S 0.62 ± 0.02 1.17 ± 0.14 2.6 ± 0.4
C32/35S 0.61 ± 0.02 0.44 ± 0.08 7.0 ± 1.3
C32/35/69S 0.43 ± 0.02 0.30 ± 0.06 7.2 ± 1.5
C62S 1.03 ± 0.04 1.14 ± 0.14 4.5 ± 0.6
C69S 1.05 ± 0.05 1.38 ± 0.19 3.8 ± 0.4
C62/69S 0.96 ± 0.03 0.61 ± 0.07 7.9 ± 1.0
C73S 0.96 ± 0.04 0.78 ± 0.11 6.2 ± 0.9
IAA-hTRX 0.56 ± 0.02 0.62 ± 0.10 4.5 ± 0.7
Kd(app), apparent binding affinity of PAD4 for hTRX variant.
(Vmax/ET )/Kd(app), pseudo activation-efficiency of hTRX variants.
active-site mutants, i.e., C35S, C32/35S, and C32/35/69S, were
redox active (Figure 4A). Interestingly, these mutants were
equally potent in activating PAD4 compared to wild type-
hTRX (Figure 4B, Table 1). In addition, other redox-active TRX
cysteine mutants (C62S, C69S, C62/69S, and C73S) behaved
like wt hTRX and showed PAD4 activation suggesting that no
individual cysteine residue is necessary for PAD4 activation
(Table 1). To test this hypothesis, we created a thiol-free variant
of TRX by chemically modifying all cysteine residues with
iodoacetamide. Indeed, IAA-treated hTRX showed no redox
activity, but it was found to be as efficient as that of other redox
active hTRX variants in enhancing the rate of PAD4-catalyzed
citrullination (Figures 4A,B).
hTRX Interaction With PAD4
We then used size-exclusion chromatography and western
blotting to investigate whether hTRX physically interacts with
PAD4 (Figures 5A,B). The reaction mixture containing hTRX
or the C32/35/69S-hTRX mutant and PAD4 yielded 3 major
peaks after passing through the size-exclusion column. The
first and second peaks represent dimeric and monomeric
PAD4 respectively, and the last peak corresponds to hTRX
(Figures 5A,B). Both PAD4 peaks were electro-transferred to a
PVDF membrane and tested for the presence of hTRX using
an anti-hTRX antibody. Samples from both redox-active hTRX
and redox-inactive C32/35/69S-hTRX showed the presence of
a corresponding hTRX band in the PAD4-containing lanes
(Figures 5A,B), suggesting that these two proteins do interact
in solution and that this interaction is not mediated though
thiol-exchange.
Next, we determined whether hTRX interacts with PAD4
in vivo using a co-IP assay. IP experiments were performed using
lysate of DMSO-differentiated HL60 cells that express higher
levels of PAD4 (47) and anti-PAD4 (rabbit) antibody (Figure 5C).
The presence of PAD4 and hTRX was evaluated in the input
(lysate), unbound fractions (supernatant), and elution fractions
(collected from the beads) using anti-PAD4 (mouse) and anti-
hTRX (mouse) antibodies. The eluate from anti-PAD4 IP shows
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FIGURE 5 | Interaction between PAD4 and hTRX. Size-exclusion chromatogram shows the elution profile of hTRX-PAD4 (A, green) and C32/35/69S-hTRX-PAD4
(B, blue) reaction mixture. The first and the second peak (marked with arrows) corresponding to dimeric and monomeric PAD4, respectively, were subjected to
denaturing SDS-PAGE and the subsequent western blot of the PAD4 peak fractions shows the presence of the corresponding hTRX variant. Co-immunoprecipitation
of hTRX with PAD4 (C). Lysate from DMSO-differentiated HL60 cells was immunoprecipitated with anti-PAD4 (rAb) followed by western blot with anti-hTRX (mAb) and
anti-PAD4 (mAb).
the presence of hTRX, confirming its interaction with PAD4
under cellular conditions (Figure 5C).
DISCUSSION
In recent decades, PAD-catalyzed citrullination has come into
focus due to its role in various autoimmune diseases including
RA. Although the precise cause of RA is unknown, it is
commonly accepted that various environmental factors (e.g.,
smoking) trigger PAD activity to generate citrullinated proteins
against which genetically susceptible individuals produce ACPAs
(48–50). Since inflammation and oxidative stress are closely
related pathophysiological processes, it has been proposed that
oxidative stress is also correlated with RA pathogenesis (51,
52). In fact, several studies show that subjects with RA have
high oxidative stress compared to healthy individuals (40, 53,
54). Mammalian cells have two major anti-oxidative defense
mechanisms: reduced glutathione (GSH) and thioredoxin
(hTRX). Although GSH is the major redox regulator, this system
is impaired during oxidative stress and therefore RA patients
show decreased (<50% of healthy controls) levels of GSH (55–
58). Despite lower GSH levels, Damgaard et al. showed that
GSH is a major physiological co-regulator of PAD activity (34).
By contrast, oxidative stress induces hTRX production during
infection and inflammation, and acts as a chemoattractant for
immune cells such as neutrophils, monocytes and T-cells (59, 60).
Consequently, hTRX levels are elevated in serum, synovial fluid,
and synovial tissues of RA patients (38–42). Here, we provide
a potential link between high TRX levels and enhanced protein
citrullination during RA.
Our data show that hTRX promotes PAD-catalyzed
citrullination in a concentration-dependent manner
(Figures 1A–D). Although hTRX is not a PAD substrate, it
exhibits Michaelis-Menten-type kinetics indicating complex
formation between these two proteins through stabilizing
interactions (61, 62). Therefore, the TRX concentration that
produces half—maximum PAD activation can be used as an
estimate for binding affinity of hTRX for PAD (similar to the
observed Km for a substrate) (Table 1). Enhanced activation of
PAD4 by DTT-treated hTRX (Figures 1A,B), and reactivation of
GSNO and H2O2-treated PAD4 by hTRX is in accord with the
fact that a reducing environment is an important requirement for
PAD activity (Figure 2A) (34). In fact, saturating concentrations
of reduced hTRX showed similar effects on PAD catalysis as
that of DTT (Figures 2A, 3). Interestingly, the optimal hTRX
concentration to activate PAD4 is 400-fold less than that of GSH
(Figure 2B), but unlike GSH (34), hTRX does not impact the
Ca2+-dependence of PAD4. Under physiological conditions,
PAD4 activity is likely regulated by the balance of these two
redox regulators and corresponding Ca2+-levels.
TRX contains two redox-active sites (Cys 32 and Cys 35)
and (Cys 62 and Cys 69). The former pair catalyzes most redox
activity, whereas the latter redox active dithiol/disulfide pair
(Cys 62 and Cys 69) is utilized under oxidizing conditions
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FIGURE 6 | Structural overlay showing redox-active sites of hTRX in various
oxidation states. Fully reduced (magenta, [PDB: 1ERT]), partially oxidized (blue,
[PDB: 1ERV]), and fully oxidized (green, [PDB: 5DQY]).
FIGURE 7 | Model depicting possible regulation of PAD4 activity upon
environmental stimuli that induces oxidative stress.
(Figure 6) (63). Therefore, converting two active-site cysteines
(Cys 32 and Cys 35) to serines yields hTRX variants devoid
of classical redox activity, while changing Cys 62 and Cys
69 to serines has no impact on redox activity (Figure 5A).
Surprisingly, redox-inactive hTRX variants, i.e., C35S, C32/35S,
and C32/35/69S activated PAD4 to catalyze citrullination
suggesting that the redox activity of TRX is not essential for PAD4
activation (Figures 4A,B). To our knowledge there are only few
prior studies featuring such TRX behavior (62, 64, 65). Liu et al.
showed that TRX promotes ASK1 ubiquitination in a redox
independent manner and that the association of TRX and ASK1
requires neither of the active site cysteines (Cys 32 or Cys 35)
(64). Similarly, Huber et al. showed that active site cysteines are
not required for TRX-dependent stimulation of DNA polymerase
activity in E. coli but substitution or alkylation of these residues
reduced the binding affinity by 60-fold indicating role for a
TRX active site in protein-protein interactions (65). On the
contrary, our data show minimal effects (one- to two-fold)
on binding of hTRX to PAD4 upon substituting redox-active
cysteines with serines (Table 1) suggesting that the activity-
enhancing interactions may occur at residues other than redox-
active cysteines. In fact, similar observations are reported for
the hTRX-dependent activation of chloroplast NADP malate
dehydrogenase and fructose-bisphosphatase where Cys32/35S
substitution had no impact on its interaction or activation profile
compared to wild type TRX. Although unusual, it is possible
that electrostatic interactions between TRX and the target protein
leads to formation of a non-covalent complex that influences the
activity of the target protein (66). Indeed, we observed physical
interactions between hTRX variants and PAD4 in in vitro studies
(Figures 5A,B) as well as in DMSO-differentiated HL60 cells
(Figure 5C). Furthermore, interactions between C32/35/69S-
hTRX and PAD4 confirmed our prior inference from kinetic data
that activity-enhancing interactions between hTRX and PAD4
occur at sites unaffected by mutation or chemical modification.
In spite of several evidences that hTRX-mediated PAD activation
does not require classical redox activity, DTT-treated hTRX
showed enhanced activation of PAD4 compared to untreated
hTRX. Such a difference can be attributed to change in binding
of hTRX with PAD4 due to subtle conformational changes
between reduced and oxidized forms of hTRX (Figure 6) (67,
68). In fact, the crystal structure of fully oxidized hTRX shows
unraveling of a helix to form an extended loop (Figure 6,
green). Since the binding affinity of oxidized and reduced hTRX
was similar, one can only assume that the structural changes
accompanying oxidation of hTRX makes the rate enhancing
interactions less productive.
Generally, it is believed that PAD4-interacting proteins might
promote its activity by lowering the Ca2+-dependence but this
is not the case with hTRX (Figure 3B). Instead, non-covalently
attached reduced hTRX likely provides localized high reduction
potential near the active site that would prevent oxidation of
the catalytic cysteine and facilitate the PAD4 catalysis. One such
scenario could arise when hTRX and PAD share a substrate, for
example, the transcription factor NF-κB. TRX is involved in the
redox regulation of NF-κB, which is a known PAD substrate.
In separate studies, Yosshida et al. showed that TRX accelerates
the nuclear translocation of NF-kB (41) and Son et al. showed
that citrullination of NF-κB enhances its nuclear localization
(69). The present study provides a link between these processes
and suggests that it could be hTRX mediated PAD4 catalyzed
citrullination that enhances the nuclear localization of NF-κB.
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Based on our findings and the existing literature, we propose
the following model to explain how environmental factors could
trigger dysregulated PAD activity (Figure 7). Environmental
factors that induce oxidative stress, such as smoking, pollution,
and infections leads to higher expression of hTRX to combat
increasing reactive oxygen species (59, 70, 71). Apart from hTRX,
oxidative stress increases intracellular concentration of Ca2+
by promoting the influx of Ca2+ from the extracellular matrix
and by releasing Ca2+ from reserves in the ER (72, 73). Thus,
oxidative stress provides perfect conditions, i.e., elevated levels
of hTRX and Ca2+, to trigger PAD activity in the cytosol as well
as in the nucleus. In fact, H2O2 treated primary murine and
human neutrophils showed enhanced PAD4-mediated histone
citrullination (74, 75). Such aberrant PAD activity in the nucleus
can cause NETosis, an event that would release active PADs into
the extracellular matrix leading to uncontrolled citrullination and
its pathogenic repercussions (Figure 7) (5–7). In summary, our
data show that hTRX regulates PAD4 activity through a non-
canonical mechanism that does not require its reducing activity;
instead, non-covalent interactions are sufficient for thioredoxin
mediated PAD activation.
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